Illumina and SPT Labtech's fireflyGO Platform Streamlines Oncology Research with Innovative Automation
In a significant step forward for the field of oncology research, Illumina, Inc. (NASDAQ: ILMN) and SPT Labtech have debuted the fireflyGO automation platform. This innovative tool is designed to simplify liquid handling and library preparation in laboratories, particularly enhancing targeted oncology research.
The fireflyGO platform is a benchtop solution that integrates seamlessly with Illumina's MiSeq™ i100 Series sequencers, offering laboratories a versatile and efficient workflow for genomic analysis. By automating critical processes, fireflyGO aims to minimize hands-on time, thus allowing researchers to focus on data interpretation rather than manual procedures.
As laboratories continue to face mounting pressures to streamline operations while maintaining integrity and accuracy in results, the introduction of fireflyGO stands to make a substantial impact. This system will enable a greater number of researchers to access and utilize next-generation sequencing (NGS) technologies, heralding a new era in cancer genomics and testing.
The collaboration between Illumina and SPT Labtech allows for the automation of library preparation, a critical component in the sequencing workflow. By reducing manual touchpoints, fireflyGO enhances reproducibility and reliability, crucial for clinical settings where precision is paramount. Sandy Ottensmann, vice president and general manager of Global Clinical Solutions at Illumina, explains, "Illumina is delivering end-to-end workflow solutions that help customers across the healthcare and research ecosystem make genomic testing more efficient and accessible."
The simplification that fireflyGO offers could potentially shorten turnaround times for results, aiming to provide quicker answers to pressing medical questions. This is particularly relevant in oncology, where timely and accurate genomic insights can lead to better treatment decisions and patient outcomes.
Alongside the fireflyGO launch, Illumina is also enhancing its Pillar Biosciences oncoReveal® targeted research portfolio. The newly expanded panels include those focused on solid tumors and hematological malignancies, all designed to provide rapid, simplified results for various cancer types. The oncoReveal® Nexus 21 Gene Panel, for instance, targets multiple cancer types like non-small cell lung cancer (NSCLC) and acute myeloid leukemia (AML).
Moreover, the oncoReveal® Lymphoid Panel covers a significant array of B-cell, T-cell, and lymphoblastic markers, aiding in the genomic characterization of lymphoid malignancies. These enhancements aim to bolster the accessibility of NGS in oncology clinical research, reinforcing Illumina's commitment to improving human health by unlocking the genome's potential.
The unveiling of the fireflyGO automation platform marks a significant advancement for genomic research labs. By integrating automation with existing Illumina technologies, this platform holds the promise of increasing the speed and efficiency of targeted oncology research. As more researchers adopt NGS technologies, the potential for groundbreaking discoveries in cancer treatment grows.
Researchers can explore the fireflyGO solutions at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing its capabilities in real-world scenarios. As Illumina continues to prioritize innovation in health care, solutions like fireflyGO exemplify the future of genomic research, paving the way for enhanced patient care and outcomes in oncology.
What is fireflyGO?
The fireflyGO platform is a benchtop solution that integrates seamlessly with Illumina's MiSeq™ i100 Series sequencers, offering laboratories a versatile and efficient workflow for genomic analysis. By automating critical processes, fireflyGO aims to minimize hands-on time, thus allowing researchers to focus on data interpretation rather than manual procedures.
As laboratories continue to face mounting pressures to streamline operations while maintaining integrity and accuracy in results, the introduction of fireflyGO stands to make a substantial impact. This system will enable a greater number of researchers to access and utilize next-generation sequencing (NGS) technologies, heralding a new era in cancer genomics and testing.
Key Features and Benefits
The collaboration between Illumina and SPT Labtech allows for the automation of library preparation, a critical component in the sequencing workflow. By reducing manual touchpoints, fireflyGO enhances reproducibility and reliability, crucial for clinical settings where precision is paramount. Sandy Ottensmann, vice president and general manager of Global Clinical Solutions at Illumina, explains, "Illumina is delivering end-to-end workflow solutions that help customers across the healthcare and research ecosystem make genomic testing more efficient and accessible."
The simplification that fireflyGO offers could potentially shorten turnaround times for results, aiming to provide quicker answers to pressing medical questions. This is particularly relevant in oncology, where timely and accurate genomic insights can lead to better treatment decisions and patient outcomes.
Expanding Genomic Testing Capabilities
Alongside the fireflyGO launch, Illumina is also enhancing its Pillar Biosciences oncoReveal® targeted research portfolio. The newly expanded panels include those focused on solid tumors and hematological malignancies, all designed to provide rapid, simplified results for various cancer types. The oncoReveal® Nexus 21 Gene Panel, for instance, targets multiple cancer types like non-small cell lung cancer (NSCLC) and acute myeloid leukemia (AML).
Moreover, the oncoReveal® Lymphoid Panel covers a significant array of B-cell, T-cell, and lymphoblastic markers, aiding in the genomic characterization of lymphoid malignancies. These enhancements aim to bolster the accessibility of NGS in oncology clinical research, reinforcing Illumina's commitment to improving human health by unlocking the genome's potential.
Looking to the Future
The unveiling of the fireflyGO automation platform marks a significant advancement for genomic research labs. By integrating automation with existing Illumina technologies, this platform holds the promise of increasing the speed and efficiency of targeted oncology research. As more researchers adopt NGS technologies, the potential for groundbreaking discoveries in cancer treatment grows.
Researchers can explore the fireflyGO solutions at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing its capabilities in real-world scenarios. As Illumina continues to prioritize innovation in health care, solutions like fireflyGO exemplify the future of genomic research, paving the way for enhanced patient care and outcomes in oncology.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.